A16. The following appeared in an article from a health magazine. “In a yearlong clinical trial of Mi-Quell, a new medicine for treating migraine headaches, researchers observed no significant side effects during the first five months. After six months, however, 20 percent of the subjects in the clinical trial began to report dizziness. Furthermore, during the final six months of the clinical trial, 43 of the subjects fell at least once and 18 were involved in automobile accidents. Such data indicate that Mi-Quell should be used to treat migraine headaches for up to six months, but after that time period doctors should prescribe another medicine.”
|